Post-publication Peer Reviews to:
|
|
|
|
|||
|
Muthukrishnan J, Senior Resident Endocrinology medwin Hospital, Hyderabad, India, KVS Harikumar, A Verma and KD Modi
Send letter to journal:
jmuthukrishnan{at}hotmail.com Muthukrishnan J, et al.
|
We read with interest the article by Nicole S. Glaser et al. We have following comments to offer: Baseline TSH receptor stimulating antibody (TSHRAb) titres and the fall in titres with anti-thyroid drug therapy has been shown to predict remission in Graves' disease.(1) Follow up titres of TSHRAb in these cohorts could have helped in prediction of remission. The dose of Propylthiouacil (PTU) used varied from 5-7 mg/kg body weight. As the BMI in the two group was different (higher in the remission group), this could have meant use of higher dose of PTU in the group having remission, thus contributing to remission. Role of ultrasound for echogenecity and color doppler flow study for vascularity of thyroid gland can help assessing disease activity and may predict remission. (2) References: 1.Cappelli C, Gandossi E, Castellano M, et al.Prognostic value of thyrotropin receptor antibodies (TRAb) in Graves' disease: a 120 months prospective study.Endocr J. 2007;54(5):713-20. 2.Vitti P, Rago T, Mazzeo S, et al.Thyroid blood flow evaluation by color- flow Doppler sonography distinguishes Graves' disease from Hashimoto's thyroiditis. J Endocrinol Invest.1995 Dec;18(11):857-61. Conflict of Interest:None declared |
|||